0RQJ Stock Chart & Stats
kr21.15
kr0.05(0.69%)
At close: 4:00 PM EST
kr21.15
kr0.05(0.69%)
Day’s Range― - ―
52-Week Rangekr11.10 - kr28.15
Previous CloseN/A
Volume372.00
Average Volume (3M)4.89K
Market Cap
kr1.74B
Enterprise Valuekr1.24B
Total Cash (Recent Filing)kr531.98M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)7.9
Beta0.89
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding138,030,140
10 Day Avg. Volume5,513
30 Day Avg. Volume4,893
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetZero debt in TTM and 2025, with sizable equity relative to assets, gives Saniona financial flexibility and reduces creditor risk. This supports continued development spending and improves resilience to funding or milestone timing.
Positive Cash GenerationRecent positive operating and free cash flow indicates that reported earnings are supported by cash generation rather than being purely accounting-driven. This can help fund research programs and reduce near-term reliance on external capital.
Strong Current ProfitabilityVery high TTM gross, operating, and net margins show strong current profitability and potentially attractive economics from licensing or collaboration income. If sustained, this profitability can strengthen internal funding capacity and partner appeal.
Bears Say
Volatile Revenue TrajectoryThe sharp reversal from a 2024 revenue surge to materially negative TTM growth indicates uneven revenue timing and limited predictability. Such volatility complicates planning, makes earnings less repeatable, and may hinder consistent pipeline investment.
History Of Cash BurnLarge historical cash outflows and recent negative free-cash-flow growth show that current cash generation may not persist across development cycles. Renewed investment needs could again pressure liquidity and increase dependence on financing or partnering.
Dependence On Partnerships And Capital RaisingA development-stage model centered on licensing deals and equity financing leaves cash resources dependent on partner interest, milestones, and investor access. Delays or unfavorable terms could constrain research progress and dilute existing shareholders.
Saniona AB News
0RQJ FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest share price was kr11.10 and its highest was kr28.15 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr1.74B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Aug 27, 2026 which is in 6 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on May 26, 2026. The company reported -kr0.334 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.334.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.334 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.024%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in GB:0RQJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Technical Analysis
Hansa Biopharma AB
―
Medivir AB
―
Camurus AB
―
AlzeCure Pharma AB
―
BioArctic AB Class B
―